Vitamin D supplementation for chronic liver diseases in adults.

The Cochrane database of systematic reviews(2021)

引用 51|浏览21
暂无评分
摘要
Given the high risk of bias and insufficient power of the included trials and the very low certainty of the available evidence, vitamin D supplementation versus placebo or no intervention may increase or reduce all-cause mortality, liver-related mortality, serious adverse events, or non-serious adverse events in adults with chronic liver diseases. There is a lack of data on liver-related morbidity and health-related quality of life. Further evidence on clinically important outcomes analysed in this review is needed.
更多
查看译文
关键词
Administration,Oral,Calcitriol [administration & dosage],Cause of Death,Cholecalciferol [administration & dosage],Chronic Disease,Ergocalciferols [administration & dosage],Hepatitis C,Chronic [blood] [complications],Hydroxycholecalciferols [administration &,dosage],Liver Cirrhosis [blood] [complications],Liver Diseases [blood] [ complications] [mortality],Liver Transplantation,Nonalcoholic,Fatty Liver Disease [blood] [complications],Randomized Controlled Trials as Topic,vham/no ["administration & dosage],[analogs & derivatives],Vitamin D Deficiency [mortality] [*therapy],Vitamins [*administration & dosage],Female,Humans,Male,Middle Aged
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要